Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

UNBELIEVABLE: 13 - Caught on Camera

COVID-19 Symptoms Rebound After Pfizer's COVID-19 Therapy, What Could Be The Reason?

Some patients have reported that COVID-19 symptoms recurred after completing treatment and experiencing improvement after Pfizer Inc's (NYSE: PFE) COVID-19 oral antiviral treatment Paxlovid.

Benzinga

Looking At Pfizer's Recent Whale Trades

Someone with a lot of money to spend has taken a bullish stance on Pfizer (NYSE:PFE). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Benzinga

Pfizer's Ex-Dividend Date Is Thursday, Here's What You Need To Know

Wednesday marks the last chance for investors to receive the next dividend payout from Pfizer (NYSE:PFE).

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Researchers Want Pfizer's Therapy Studied As Evidence Suggests Benefit for Long COVID Patients: Reuters

Additional reports of patients with long COVID who were helped by Pfizer Inc's (NYSE: PFE) oral antiviral treatment Paxlovid have surfaced, providing momentum for conducting clinical trials to test the treatment,

Benzinga

FDA Berates Pfizer CEO's Suggestion To Take More Paxlovid If COVID-19 Symptoms Rebound

The FDA berates Pfizer Inc (NYSE: PFE) CEO Albert Bourla's proposed solution in cases where virus levels rebound after the first course of treatment.

Benzinga

3 Mega-Cap Stocks You'll Regret Not Buying on the Dip

The Fed's plan to raise interest rates aggressively has aggravated bearish investor sentiment ahead of the Federal Reserve Board meeting this week. And rising recessionary fears are expected to sustain the bearish mood in the near term. However, quality mega-cap stocks Abbott (ABT), Broadcom (AVGO), and Pfizer (PFE) are expected…

StockNews.com

Pfizer Posts Street Beating Q1 Earnings, Revises FY22 Profit Outlook

Pfizer Inc (NYSE:PFE) has reported a Q1 adjusted EPS of $1.62, up 72% Y/Y, well ahead of the consensus of $1.50. The company achieved revenues of $25.66 billion, up 77%, beating the Wall Street estimate of $23.95 billion. Its COVID-19 vaccine, Comirnaty, contributed $13.2 billion in direct sales and alliance revenues. Eliquis…

Benzinga

Read news from The Economist, FT, and more,
with one subscription

3 High-Quality Stocks to Buy During This Market Selloff

The near-term market outlook remains cloudy. While the S&P 500 is about 3% above its late-February lows, the Nasdaq and Russell 2000 have already undercut these levels. Below are 3 such stocks that investors should consider buying during this market correction: Anthem (ANTM), Pfizer (PFE), and Builders FirstSource (BLDR).

StockNews.com

FDA Gives Green Signal To Pfizer's Duchenne Gene Therapy Trial

After the FDA lifted its hold on a late-stage study, Pfizer Inc (NYSE:PFE) said it would open the first U.S. trial sites for its experimental gene therapy for a muscle-wasting disorder. The FDA had put Pfizer's Investigational New Drug (IND) application for fordadistrogene movaparvovec on hold, and Pfizer has addressed the agency's requests related…

Benzinga

Pfizer, BioNTech Seeks Emergency Use Nod For COVID-19 Vaccine For Kids 5-11 Years

Pfizer Inc (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX) have submitted an FDA Emergency Use Authorization (EUA) application for a 10-µg booster dose of COVID-19 Vaccine for children 5 through 11 years of age. The submission included data from the Phase 2/3 clinical trial in children ages 5 through 11 years who received a booster dose…

Benzinga

Valneva - Pfizer Post Encouraging Data From Lyme Disease Vaccine Candidate

Valneva SE (NASDAQ:VALN) and Pfizer Inc (NYSE:PFE) have reported Phase 2 pediatric data for their Lyme disease vaccine candidate, VLA15. In pediatric participants (5-17 years old) who received VLA15 in either the two-dose schedule (N=93) or three-dose schedule (N=97), VLA15 was found to be more immunogenic than in adults with both vaccination schedules tested. These…

Benzinga

Pfizer Recalls Some Batches Of Another Hypertension Drug Over Cancer-Causing Impurity

Pfizer Inc (NYSE:PFE) said it is voluntarily recalling five batches of its Accupril blood pressure tablets after finding elevated levels of a potential cancer-causing agent in the medicine. Accupril is indicated for hypertension to lower blood pressure. It is also indicated for the management of heart failure as adjunctive therapy when added to…

Benzinga

Looking for Value Stocks to Add to Your Portfolio? Here are 5 For Your List

Heightened inflationary pressure, deepening supply chain disruptions, and the possibility of aggressive interest rate hikes later this year have fostered a volatile stock market. Because these factors are not expected to abate anytime soon, we think investors looking to generate solid long-term returns could consider betting on the stocks of…

StockNews.com

Pfizer/BioNTech Fourth COVID-19 Vaccine Dose Protects Against Omicron For At Least One Month

A fourth dose of the COVID-19 vaccine from Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) provided significant protection against severe disease, hospitalization, and death for at least a month i

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Two long COVID Patients Recover After Pfizer's Therapy; Side Effects, Safety Needs To Be Assessed: Reuters

Reuters reported that two patients found relief from long COVID after taking Pfizer Inc's (NYSE:PFE) antiviral Paxlovid, including a researcher who tested it on herself. Long COVID is estimated to affect up to 30% of people infected with the coronavirus. It can last for months. More than 200 symptoms have been associated with the…

Benzinga

Pfizer/BioNTech's COVID-19 Vaccine Booster Shows High Immune Response In Kids Aged 5-11 Years

Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) have announced results from a Phase 2/3 trial of a 10 µg booster (third) dose of COVID-19 vaccine in children aged 5-11 years.

StockNews.com

5 Global Healthcare Stocks to Buy as BofA Warns of a "Recession Shock"

The healthcare industry is well-positioned to ride out a potential recessionary shock, thanks in-part to the inelastic demand for COVID-19 vaccines worldwide. Thus, we think investors could invest in fundamentally sound healthcare stocks Pfizer Inc. (PFE), Johnson & Johnson (JNJ), AbbVie Inc. (ABBV), Eli Lilly and Company (LLY), and Merck…

Benzinga

Pfizer Beefs Up Its RSV Antiviral Portfolio With $525M ReViral Acquisition

Pfizer Inc (NYSE: PFE)

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Pfizer/BioNTech's Second COVID-19 Vaccine Booster Provides Short-Lived Protection In Elderly, Israel Study Shows

An Israel-based study has found that a fourth dose of the Pfizer Inc (NYSE: PFE) / BioNTech SE (NASDAQ: BNTX) vaccine lowered rates of COVID-19 infection among the elderly.

Benzinga

Pfizer/BioNTech's COVID- Vaccine Cuts Hospitalization Risk In Kids Aged 5-11 Years: Reuters

According to a US-based study, children ages 5 to 11 who received the Pfizer Inc (NYSE:PFE) / BioNTech SE's (NASDAQ:BNTX) COVID-19 vaccine were 68% less likely to be hospitalized during the omicron wave than unvaccinated children. Adolescents aged 12-18 who received two shots of the vaccine were around 40% less likely to be hospitalized with the…

Benzinga

FDA Approves ViiV Healthcare's Cabenuva For Virologically Suppressed Adolescents With HIV

The FDA has approved ViiV Healthcare's Cabenuva (cabotegravir, rilpivirine) for HIV-1 in virologically suppressed adolescents. The approval covers patients aged 12 years or older and weighing at least 35kg on a stable antiretroviral regimen, with no history of treatment failure and no known or suspected resistance to either cabotegravir or rilpivirine. The regimen…

StockNews.com

3 Healthcare Stocks to Buy for the Long Run

The healthcare industry has achieved significant growth over the past two years in-part because the COVID-19 pandemic fostered a stream of hefty private and federal investments in the sector. With accelerating advancement and increased tech integration in healthcare, we expect renowned companies Pfizer Inc. (PFE), Merck & Co., Inc. (MRK),…

Benzinga

Pfizer's Second Etrasimod Phase 3 Ulcerative Colitis Trial Hits Primary Goal

Pfizer Inc (NYSE:PFE) has announced topline results from a second Phase 3 study of etrasimod for moderately to severely active ulcerative colitis (UC). The 12- and 52-week ELEVATE UC 52 follow the recent announcement of 12-week findings from the ELEVATE UC 12 trial. In this 52-week study, also known as ELEVATE UC 52,…

Benzinga

Pfizer's COVID-19 Oral Therapy To Be Tested In Hospitalized COVID-19 Patients In UK: Reuters

Pfizer Inc's (NYSE: PFE) oral COVID-19 therapy will be evaluated as a potential treatment for hospitalized COVID-19 patients in a major British trial.

StockNews.com

3 Vaccine Stocks to Buy Following the Surge in COVID-19 Cases in China

China is battling with its worst COVID-19 outbreak since 2020. Surging cases of a new omicron variant worldwide are raising concerns that another COVID-19 wave is coming, which could drive demand for future vaccine orders. This bodes well for popular vaccine stocks Pfizer (PFE), Moderna (MRNA), and BioNTech (BNTX), and…

1 … 12 13 14 15

People

Albert Bourla

85 stories

Jaimini DesaiJaimini Desai

59 stories

Jaimini Desai

10 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.